Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients
12 juin 2024 07h00 HE
|
Athira Pharma, Inc.
Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients
Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
11 juin 2024 07h00 HE
|
Athira Pharma, Inc.
Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
Athira Pharma to Participate in Upcoming June Conferences
29 mai 2024 07h00 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., May 29, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action
17 mai 2024 17h00 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., May 17, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
15 mai 2024 16h05 HE
|
Athira Pharma, Inc.
Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
Athira Pharma to Participate in Upcoming May Conferences
02 mai 2024 07h00 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., May 02, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
15 avr. 2024 07h00 HE
|
Athira Pharma, Inc.
Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer.
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
11 avr. 2024 07h00 HE
|
Athira Pharma, Inc.
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
03 avr. 2024 07h00 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., April 03, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing novel small molecules to restore neuronal...
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
08 mars 2024 07h00 HE
|
Athira Pharma, Inc.
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s & Parkinson’s Diseases at AD/PD™ 2024